These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 3471687)
1. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687 [TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen]. Olsson NO; Crimet-Montange D; Martin F Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449 [TBL] [Abstract][Full Text] [Related]
3. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Kuusela P; Haglund C; Roberts PJ Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550 [TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis]. Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133 [TBL] [Abstract][Full Text] [Related]
6. [Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA]. Pecchio F; Piantino P; Oliaro A; Rapellino M; Ricci E; Aimo G; Obert R Minerva Med; 1986 Nov; 77(42-43):1973-81. PubMed ID: 3464850 [TBL] [Abstract][Full Text] [Related]
7. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma. Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396 [TBL] [Abstract][Full Text] [Related]
8. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110 [TBL] [Abstract][Full Text] [Related]
9. Tumour marker CA 125 in patients with digestive tract malignancies. Haglund C; Kuusela P; Roberts P; Jalanko H Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125 [TBL] [Abstract][Full Text] [Related]
11. [Serum level of tumor markers (antigen Ca 19-9, CEA, ferritin) in digestive tumors. Their diagnostic usefulness]. Jovin G; Stănel I; Popovici I; Oproiu A Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(3):223-9. PubMed ID: 2904162 [No Abstract] [Full Text] [Related]
13. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Kuusela P; Haglund C; Roberts PJ; Jalanko H Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731 [TBL] [Abstract][Full Text] [Related]
14. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer]. Anzai K; Kurihara M; Izumi T Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836 [TBL] [Abstract][Full Text] [Related]
15. Tumour markers in pancreatic cancer. Haglund C; Roberts PJ; Kuusela P; Jalanko H Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921 [TBL] [Abstract][Full Text] [Related]
16. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Haglund C; Roberts PJ; Jalanko H; Kuusela P Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477 [TBL] [Abstract][Full Text] [Related]
17. Carcinoembryonic antigen (CEA) and gastrointestinal cancer associated antigen CA 19-9 in bronchioloalveolar carcinomas and pulmonary adenocarcinomas. Heikkilä L; Suomalainen RJ; Lindgren J; Jalanko H; Harjula A; Mattila S Ann Chir Gynaecol; 1986; 75(5):260-5. PubMed ID: 3030184 [TBL] [Abstract][Full Text] [Related]
18. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076 [TBL] [Abstract][Full Text] [Related]
19. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731 [TBL] [Abstract][Full Text] [Related]
20. Tissue distribution of 2-3 and 2-6 sialyl Lewis A antigens and significance of the ratio of two antigens for the differential diagnosis of malignant and benign disorders of the digestive tract. Itai S; Nishikata J; Yoneda T; Ohmori K; Yamabe H; Arii S; Tobe T; Kannagi R Cancer; 1991 Mar; 67(6):1576-87. PubMed ID: 2001547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]